Why Europe must future-proof its pharma legislation
- harmonising processes that are now too fragmented between EU and national level
- expanding the EMA role where science is evolving (e.g. drug-device combinations)
- addressing any resource gaps related to both current and future workload.
For European citizens, our health systems and our economy, we must act decisively to reverse Europe’s decline in this vital field. The alarm bells are ringing and we must all play our part to reinvent our regulatory environment as part of a wider push to ensure an innovation-friendly ecosystem in Europe.